Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.dovepress.com/selective-estrogen-receptor-modulators-tissue-specificity-and-clinical-peer-reviewed-fulltext-article-CIA, but it redirected us to https://www.dovepress.com/selective-estrogen-receptor-modulators-tissue-specificity-and-clinical-peer-reviewed-fulltext-article-CIA. The analysis below is for the second page.

Title[redir]:
Selective estrogen receptor modulators: tissue specificity and clinica | CIA
Description:
Selective estrogen receptor modulators: tissue specificity and clinical utility Stephen Martinkovich,* Darshan Shah,* Sonia Lobo Planey, John A ArnottDepartment of Basic Sciences, The Commonwealth Medical College, Scranton, PA, USA*These authors contributed equally to this workAbstract: Selective estrogen receptor modulators (SERMs) are a diverse group of ­nonsteroidal compounds that function as agonists or antagonists for estrogen receptors (ERs) in a target gene-specific and tissue-specific fashion. SERM specificity involves tissue-specific expression of ER subtypes, differential expression of co-regulatory proteins in various tissues, and varying ER conformational changes induced by ligand binding. To date, the major clinical applications of SERMs are their use in the prevention and treatment of breast cancer, the prevention of osteoporosis, and the maintenance of beneficial serum lipid profiles in postmenopausal women. However, SERMs have also been found to promote adverse effects, including thromboembolic events and, in some cases, carcinogenesis, that have proven to be obstacles in their clinical utility. In this review, we discuss the mechanisms of SERM tissue specificity and highlight the therapeutic application of well-known and emergent SERMs.Keywords: selective estrogen receptor modulators, SERMs, estrogen receptors

Matching Content Categories {πŸ“š}

  • Health & Fitness
  • Science
  • Insurance

Content Management System {πŸ“}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {πŸ“ˆ}

What is the average monthly size of doi.org audience?

πŸ™οΈ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 76,004,851 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {πŸ’Έ}

We can't tell how the site generates income.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org could be secretly minting cash, but we can't detect the process.

Keywords {πŸ”}

tamoxifen, cancer, estrogen, breast, receptor, effects, raloxifene, endometrial, women, treatment, phase, selective, serms, postmenopausal, erΞ±, res, bone, idoxifene, activity, cell, risk, trial, droloxifene, bazedoxifene, serm, binding, tissue, patients, cells, compared, group, osteoporosis, drug, dna, trials, chem, arzoxifene, clinical, erΞ², effect, response, study, tor, estrogens, therapy, determined, growth, results, increased, lasofoxifene,

Topics {βœ’οΈ}

population-based case-control study raloxifene-estrogen receptor-alpha complex tamoxifen-bound estrogen receptor-alpha pre-osteoclast apoptosis lambda/laci transgenic rats dove medical press estrogen receptor/coactivator recognition selective estrogen receptor-beta estrogen receptor-selective coregulator including fast-track processing mixed agonism/antagonism profile tissue-selective estrogen complex ligand-dependent receptor conformational er-positive breast cancer manuscript login hormone receptors estrogen-alpha eralpha-agonist induced proliferation tamoxifen-complexed estrogen receptor ligand-dependent nuclear er distinct chromatin-modifying complexes histone de-acetylase activity endometrial k-ras mutations study progression-free survival ligand-induced transcriptional activation anti-estrogenic side chain selective receptor modulators specific author advanced breast cancer favored authors patient-level meta-analysis hormone-sensitive advanced shorter serum half-life tamoxifen-derived dna adducts single chloride atom cellular eralpha/erbeta ratio indole-based er ligand dna adduct-forming ability strong anti-estrogenic effects women mid-luteal phase differential time-dependent inactivation placebo-controlled crossover study nonsteroidal estrogen agonist/antagonist anti-estrogenic erΞ± complex partial estrogen-agonist properties androgen deprivation therapy bazedoxifene-conjugated estrogens combination prevent endometrial-breast cancer human estrogen receptor early breast cancer tissue-specific effects compared

Questions {❓}

  • Why publish with us?

Social Networks {πŸ‘}(9)

External Links {πŸ”—}(421)

Analytics and Tracking {πŸ“Š}

  • Google Analytics
  • Google Tag Manager

Libraries {πŸ“š}

  • jQuery

Emails and Hosting {βœ‰οΈ}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {πŸ“¦}

  • Com/cm/ef49a3f1-d8c1-47d6-88fc-50e41130631f/airgap

5.72s.